pharmaphorum
NOVEMBER 9, 2022
The keynote address of the event entire came from Stella Kyriakides, commissioner for health and food safety at the European Commission. In September, the EU launched its recommendations on cancer screening, updated for the first time since 2003. Collaborating and committing to innovation, equity, and cancer care across Europe.
European Pharmaceutical Review
JULY 20, 2023
Covered SoHO activities are “action[s], or series of actions, that [have] a direct impact on safety, quality or efficacy of SoHOs.” This will enable better monitoring of the safety and quality of these products, but it may also require additional investments in IT infrastructure.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
FEBRUARY 3, 2023
A partial change in perspectives The RV144 trial that took place between 2003 and 2006 in Thailand r eported modest efficacy results , which generated enthusiasm for vaccines that induce responses from non-neutralising antibodies, says Montefiori. The third cohort features the highest studied dose.
European Pharmaceutical Review
SEPTEMBER 22, 2023
7 It is currently being evaluated in a Phase Ib/IIa clinical study, demonstrating to date a good safety profile. While favourable safety has been reported up to the Phase II, the relevance of targeting the C-terminal portion of Abeta still needs to be confirmed. Andrea Pfeifer, PhD In 2003, Andrea Pfeifer co-founded AC Immune SA.
European Pharmaceutical Review
MARCH 11, 2024
With therapeutic expertise in HIV, hepatology and rare diseases, Sherene has additional expertise in clinical pharmacology and drug safety. Sherene has worked in the healthcare sector for more than 20 years, including in several leadership roles at GSK. References 1. World Health Organization. The Global Health Observatory. Internet] 2023.
Medico Reach
JUNE 20, 2024
Cutera has evolved into a global leader in dermatology and aesthetics devices that fascinate forward-thinkers pursuing the next generation of performance, safety and effectiveness. Location: California Website: sientra.com Established year: 2003 Revenue: $90.3
Pharmaceutical Technology
AUGUST 26, 2008
.” By the early 2000s AstraZeneca had already realised the critical importance of biotechnology, making a number of strategic investments in biotech companies, Abgenix in 2003, Cambridge Antibody Technology in 2006 and culminating in its acquisition of US biotech firm, Medimmune in April 2007 for £15bn.
Expert insights. Personalized for you.
98 
Let's personalize your content